Literature DB >> 10532679

Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters.

Y Asami1, I Yamagishi, K Akiyoshi, H Tomoike, K Tsuchida, S Higuchi.   

Abstract

The hypocholesterolemic and anti-atherosclerotic effect of TS-962, a specific ACAT inhibitor, was investigated in a hamster model fed a high fat diet containing 10% coconut oil and 0.05% cholesterol. Lipid accumulated atherosclerotic lesions were detected by using oil red O staining in the lesion-prone aortic arch. A high dose, estimated to be 15 mg/kg, of TS-962 decreased serum cholesterol to normal levels with reduction of liver cholesterol contents below normal levels, and as a consequence, entirely inhibited the lipid accumulation in the aortic arch. Furthermore, a low dose, estimated to be 1.5 mg/kg, of TS-962 remarkably inhibited aortic lipid accumulation by 73% compared with the control group, without changing either serum cholesterol level or liver cholesterol content. These findings suggest that TS-962 is effective in the primary prevention of atherosclerosis by directly suppressing the formation of foam cells in arteries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532679     DOI: 10.1016/s0021-9150(99)00141-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

Review 1.  LDL-C-lowering therapy: current and future therapeutic targets.

Authors:  Maartje E Visser; Lily Jakulj; John J P Kastelein; Erik S G Stroes
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

Review 2.  Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?

Authors:  Therese M Heinonen
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 3.  Treating hypercholesterolemia: looking forward.

Authors:  Antonio M Gotto
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

Review 4.  Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Authors:  Marc Evans; Aled Roberts; Steve Davies; Alan Rees
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.